Výsledky vyhledávání

Akademický článek

Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies.

Autor: Chen Y; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)., Nagaraja NV; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.) raj.nagaraja@servier.com., Fan B; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)., Utley L; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)., Lemieux RM; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)., Popovici-Muller J; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)., Dang L; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)., Kim H; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)., Yan L; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)., Su SM; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)., Biller SA; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.)., Yang H; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts (Y.C., N.V.N., B.F., L.U., R.M.L., J.P.-M., L.D., H.K., S.-S.M.S., S.A.B., H.Y.); ChemPartner, Shanghai, China (L.Y.); Servier Pharmaceuticals LLC, Boston, Massachusetts (N.V.N.); KLUS Pharma, Cranbury, New Jersey (B.F.); Ribon Therapeutics, Cambridge, Massachusetts (L.U.); Faze Medicines, Inc., Cambridge, Massachusetts (R.M.L.); Rectify Pharmaceuticals, Cambridge, Massachusetts (J.P.-M.); Volastra Therapeutics, Inc., New York, New York (S.-S.M.S.); and Disc Medicine, Cambridge, Massachusetts (H.Y.).

Publikováno v: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2021 Oct; Vol. 49 (10), pp. 870-881. Date of Electronic Publication: 2021 Jul 28.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání